





Blood pressure is closely linked to arterial stiffness. A few studies have examined the longitudinal association of blood pressure with arterial stiffness progression and the results were inconsistent. Brachial-ankle pulse wave velocity, a combined measure of central and peripheral arterial stiffness, is easier to perform and with higher reproducibility than carotid-femoral pulse wave velocity but similarly predicts cardiovascular events. The objective of the present study was to investigate the roles of initial blood pressure and its longitudinal increase on the progression of arterial stiffness measured using brachial-ankle pulse wave velocity. Study participants (n=656) were from population-based samples of healthy men aged 40–49 at baseline (213 White American, 47 African American, 152 Japanese American and 244 Japanese in Japan). Systolic and diastolic blood pressures, pulse pressure, mean arterial pressure, brachial-ankle pulse wave velocity, and other factors were examined at baseline and 4-7 years later. Annual change in systolic blood pressure, but not its baseline level, had a positive significant association with the progression of brachial-ankle pulse wave velocity even after adjusting for a wide range of other cardiovascular risk factors. Similarly, annual changes in diastolic, pulse and mean arterial pressures were positively associated with the progression of brachial-ankle pulse wave velocity. None of the baseline measures were related to the progression of brachial-ankle pulse wave velocity over time. In sum, increase in blood pressure was a strong predictor of the progression of brachial ankle pulse wave velocity among apparently healthy multi-national middle-aged men. Our findings demonstrate that, annual change in blood pressure, but not its initial values, is positively and significantly associated with the progression of arterial stiffness, indicating that a rise in blood pressure independently contributes to more increase in arterial stiffening. Cardiovascular disease is the leading cause of death both in the United States and worldwide; hypertension is the leading remediable risk factor for cardiovascular disease. These results have public health significance with regard to stressing the important practical issues of effectively controlling blood pressure to reduce vascular damage and cardiovascular risks.
TABLE OF CONTENTS
 TOC \o "2-4" \h \z \t "Heading 1,1,Appendix,1,Heading,1" 1.0	Introduction	1
2.0	Methods	3







3.2	Blood pressur and baPWV progression	8
4.0	Discussion	13
4.1	Major Findings	13
4.2	accelarated blood pressure with bapWV progression	13
4.3	initial blood pressure with baPWV progression	14
4.4	baPWV versus cfPWV	15






 TOC \h \z \c "Table" Table 1. Baseline characters of the study population overall and by race	10
Table 2. Annual Changes in blood pressure (SBP, DBP, PP and MBP) (n=656)	11
Table 3. Association of baseline and annual changes of blood pressure with baPWV progression (systolic, diastolic, pulse and mean arterial pressure) in general linear models (n=656)	11
Table 4. Association of baseline and annual changes in blood pressure (systolic, diastolic, pulse and mean arterial pressure) with baPWV progression (relative annual change >1% versus ≤1% per year) in logistic regression analysis (n=656)	12
Table 5. Comparison baseline characters for subjects between who included and excluded	20
Table 6. Interaction terms in fully adjusted model	22
List of figures







Arterial wall stiffening, occurring in early midlife and advancing with age1,2, represents a loss of normal arterial compliance and is recognized as one of the earliest detectable signs of functional and structural changes in the arterial wall3,4.  It has been widely identified as an independent determinant of cardiovascular morbidity and mortality5–8. A most recent scientific statement from the American Heart Association recommended that arterial stiffness provides incremental information beyond standard cardiovascular risk factors in the prediction of future cardiovascular event9.  Currently, the most widely used and validated surrogate measure of arterial stiffness is pulse wave velocity (PWV)9,10. 
Greater stiffening of arterial walls is closely linked to raised blood pressure11. Cross-sectional data have consistently shown a strong relation between blood pressure and arterial stiffness12,13. However, longitudinal study results have been inconclusive with regards to the association of blood pressure with arterial stiffness progression14–18. AlGhatrif et al15 reported that accelerated systolic blood pressure was significantly associated with progression of carotid-femoral PWV (cfPWV) progression; on the other hand, Scuteri et al14 observed that blood pressure was not related to the progression of cfPWV over time. Neither of these two studies assessed the potential effect of baseline blood pressure on arterial stiffness progression. Knowing the patterns of the longitudinal relation of blood pressure with arterial stiffness is needed to better understand the potential mechanisms underlying arterial wall stiffening. Such information might be helpful for future investigations aimed at slowing and reducing the stiffening of arterial walls. 
cfPWV measures the pulse velocity as it travels from the heart to the carotid and the femoral artery, primarily reflecting central arterial stiffening19. It is considered the gold standard measure of arterial stiffness10. An emerging automatic measure of PWV is brachial-ankle PWV (baPWV). It is a combined measure of central and peripheral arterial stiffness20,  yet baPWV is highly correlated with cfPWV (correlation coefficient r=0.73)21. However, to date very few studies have investigated potential determinants of baPWV progression. 
To the best of our knowledge, no previous study has examined the association of both the initial blood pressure as well as its longitudinal change with arterial stiffness progression using baPWV. Using population-based samples of apparently healthy men from the Electron-Beam Computed Tomography and Risk Factor Assessment in Japanese and US Men in the Post-World War II Birth Cohort (ERA JUMP) study22, we aimed to evaluate: 1) whether longitudinal changes in blood pressure are significantly associated with baPWV progression independent of other cardiovascular risk factors; and 2) the ability of baseline blood pressure to predict baPWV progression over seven years of follow up. 
2.0 	Methods
2.1	Study Participants and Analytic Sample
All study participants were from the ERA JUMP study, a population-based study of men aged 40 to 49 years without cardiovascular or other severe diseases at baseline during 2004-2007 as described previously22. Of 1033 subjects, 310 White Americans and 107 African American were from Allegheny County, Pennsylvania; 303 Japanese Americans were from Honolulu, Hawaii; and 313 Japanese were from Kusatsu, Shiga, Japan. After excluding 377 (28.2%) participants either those who did not come to follow-up visit (246 participants) or those who had missing data of baPWV (131 participants), our final analytic sample included 656 participants (213 White Americans, 47 African Americans, 152 Japanese Americans and 244 Japanese in Japan). Participants who were excluded from the current analyses were more likely to be African American or Japanese American, more hypertension medication users, had higher levels of body mass index (BMI) and heart rate. There was no significant difference in baseline measures of baPWV, blood pressure (systolic, diastolic, pulse and mean arterial pressure), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglyceride, age, smoking, or diabetes (Online supplemental data table S1). Informed consents were obtained from all study participants. 
2.2	blood pressure
At each study center, blood pressure was measured both at baseline and at follow-up visits, in a sitting position, in the right arm after the participants had emptied their bladders and sat quietly for five minutes, using an appropriate-sized cuff and an automated sphygmomanometer (BP-8800; Colin Medical Technology, Komaki, Japan). The blood pressure values used in this study were an average of two measurements during each visit. Pulse pressure was defined as the difference between systolic blood pressure and diastolic blood pressure, and mean arterial pressure was calculated as 1/3 (systolic blood pressure−diastolic blood pressure) + diastolic blood pressure.
2.3	BaPWV
baPWV was measured at both baseline and follow-up visits using a noninvasive automated waveform analyzer (VP2000, Omron Co., Komaki, Japan) and using appropriate-sized cuffs at each study center, as described previously22. Following ten minutes of rest in the supine position, occlusion and monitoring cuffs were placed around both arms and ankles and ECG electrodes were placed on both wrists and a phonocardiogram on the left edge of sternum. The path lengths for baPWV were calculated using a height-based formulae23. baPWV was calculated as the distance between arterial sites divided by the time between the feet of the respective waveforms. For both left and right baPWV measures, data was collected twice for each participant and the observed values were averaged during each visit. Before conducting the baPWV measures, all research technicians from each study site received standard training provided by the Ultrasound Research Laboratory at the University of Pittsburgh. Intra-class correlations for baPWV measurement were 0.97 within technicians and 0.91 between technicians24. The average value of the left and right baPWV measures was used in the present analyses.  
2.4	Other Covariates
All participants underwent a physical examination, laboratory assessment, and lifestyle questionnaire both at baseline and follow-up visits as described previously22. Data collection was standardized at each study center. Age, follow-up time, smoking status (equal or greater than twenty pack-years or not), and the use of antihypertensive and lipid-lowering medications were assessed via questionnaires; and BMI and heart rate were assessed during the examination. Serum samples were collected in the morning after a 12-hour fast, stored at -80°C and shipped on dry ice to the Heinz Nutrition Laboratory, University of Pittsburgh for analysis. Serum lipids, including HDL-C, LDL-C, and triglycerides, were determined using standardized methods of the Centers for Disease Control and Prevention. Serum glucose was determined using a hexokinase glucose-6-phosphate-dehydrogenase enzymatic assay. Diabetes was defined as the use of blood glucose lowering drugs, or fasting blood glucose level ≥7.0 mmol/L.
2.5	Statistical Analyses
baPWV progression was assessed as the relative annual change in baPWV (%) by calculating the ratio of the annual change to the baseline baPWV * 100. baPWV, blood pressure (systolic, diastolic, pulse and mean arterial pressure), and other covariates were calculated overall and stratified by races at baseline. For blood pressure (systolic, diastolic, pulse and mean), BMI, HDL-C, LDL-C and triglycerides, annual changes were calculated and evaluated. Categorical variables were presented as number (%) and continuous variables as mean (standard deviation (SD)) or median (interquartile range (IQR)) based on the distribution of the data. 
A general linear regression analysis was used to assess the association of each blood pressure measure (the baseline and annual change) with baPWV progression. For the multivariable analyses, we used four models to progressively adjust for potential confounders. We initially adjusted for age, race and heart rate (model 1); model 2 = model 1 plus BMI, smoking status, hypertension medication, and diabetes; model 3 = model 2 plus HDL-C, LDL-C, triglycerides, and lipid-lowering medication; and model 4 (fully adjusted model) = model 3 plus annual change in BMI, HDL-C, LDL-C, and triglycerides. The strategy of model selection was based on a recent systematic review12, suggesting a strong association of arterial stiffness with age and blood pressure, a moderate association with diabetes,  and a non-significant association with HDL-C, LDL-C, or triglycerides. Logistic regression analysis was used to assess the association of baPWV progression (greater than 1% per year or not) with baseline and annual change values of blood pressure, adjusting for all of the above-mentioned covariates in order from model 1 to model 4. Each blood pressure measure, including systolic, diastolic, pulse and mean arterial pressure, were assessed separately for each model mentioned above. 
Log transformation was applied to highly skewed variables, which were HDL-C and triglycerides, and the annual change of those two variables. Two-sided P<0.05 were considered statistically significant. All analyses were performed with SAS v9.4 (SAS Institute, Cary, NC). 
3.0 	Results
3.1	Decriptive analyses
A total of 656 participants were included in the present study. The study population had a mean age of 45.2 years at baseline (ranging from 40 to 49 years) and was followed for an average of 5.7 years (ranging from 4.0 to 7.9 years). Table 1 presents the demographic characteristics and the clinical measures for the overall study population and by race. At baseline, the overall mean (SD) baPWV was 1346.2 (174.6) cm/s; the overall means (SD) of systolic blood pressure, diastolic blood pressure, pulse pressure and mean arterial pressure were 124.6 (13.8), 75.4 (10.4), 16.4 (2.6), and 91.8 (11.1) mmHg, respectively. 
The relative annual change in baPWV (%), ranged from -4.8 to 6.0, and was normally distributed with a mean (SD) of 0.7(1.7), which was significantly different from zero (P<0.001) (Figure 1). Of all study participants, 66% had a relative annual change in baPWV of greater than 0 and 42.1% had a value greater than 1%. The annual change in systolic blood pressure, diastolic blood pressure, pulse pressure and mean arterial pressure were also approximately normally distributed, with mean (SD) of 0.3 (2.3), 0.6 (1.6), -0.3 (1.6) and 0.5 (1.7) mmHg, respectively (Table 2). The means (SD) (or medians (IQR)) of annual changes in BMI, HDL-C, LDL-C and triglycerides were 0.1(0.4) kg/m2, 0.01 (-0.01, 0.04) mg/dL, -0.02 (0.16) mg/dL and -0.01 (-0.08, 0.06) mg/dL, respectively.  
3.2	Blood pressur and baPWV progression
Table 3 presents multivariable-adjusted linear regression analyses of each individual blood pressure measure (systolic, diastolic, pulse and mean arterial pressure) with both baseline and annual change. Annual change in systolic blood pressure, but not the baseline value, had a positive significant association with baPWV progression after adjusting for age, race, and heart rate (model 1). The associations remained significant after further adjusting for body mass index (BMI), smoking status, hypertension medication use, and diabetes (model 2); after further adjusting for HDL-C, LDL-C, triglycerides, and lipid-lowering medication (model 3); and after additionally adjusting for annual changes in BMI, HDL-C, LDL-C, and triglycerides (model 4). Annual changes in diastolic blood pressure, pulse pressure and mean blood pressure also had significant positive association with baPWV progression, respectively. Similarly, none of the baseline values for the blood pressure measures were associated with baPWV progression in the multivariable-adjusted analyses (models 1 to 4). We found no significant interactions between race and each of blood pressure measures in multivariable-adjusted regression models for baPWV progression (Online data supplement Table S2).  




The relative annual change in baPWV ranged from -4.8 to 6.0% and was normally distributed. The mean (standard deviation) was 0.7(1.7) %, with 66.6% of the study participants having a relative annual change of baPWV greater than 0 and 42.1% having a value greater than 1%. The negative values represent a reduction, while positive values represent an increase in baPWV over the follow-up time relative to baseline levels.


Table 1. Baseline characters of the study population overall and by race

		Race
	Overall N=656	White Americann=213	African Americann=47	Japanese Americann= 152	Japanese in Japann=244
Baseline*					
Age (years)	45.2 (2.9)	45.0 (2.9)	45.0 (3.0)	46.0 (2.9)	45.0 (2.8)
Follow-up time (years)	5.7 (0.9)	4.6 (0.2)	4.5 (0.3)	6.6 (0.6)	6.2 (0.3)
BMI (kg/m2)	26.3 (4.3)	27.5 (3.6)	30.0 (6.6)	27.5 (4.0)	23.7 (3.1)
Smoking ≥20 pack-years (n (%))	141 (21.5)	14 (6.6)	2 (4.3)	12 (7.9)	113 (46.3)
Heart rate (beats/min)	65.1 (8.8)	64.5 (9.0)	65.5 (9.7)	66.4 (8.7)	64.8 (8.5)
Blood pressure (mmHg)					
   SBP	124.6 (13.8)	122.6 (11.1)	123.1 (14.6)	127.4 (12.6)	124.9 (16.1)
   DBP	75.4 (10.4)	73.3 (8.5)	73.1 (11.3)	77.4 (9.5)	76.4 (11.9)
   PP	16.4 (2.6)	16.4 (2.3)	16.7 (2.8)	16.7 (2.4)	16.2 (2.8)
   MBP	91.8 (11.1)	89.7 (8.8)	89.7 (11.8)	94.1 (10.0)	92.5 (12.9)
Hypertension medication (n (%))	66 (10.1)	17 (8.0)	7 (14.9)	29 (19.1)	13 (5.3)
HDL-C (mmol/L)	1.3 (1.1, 1.5)	1.2 (1.0, 1.4)	1.2 (1.1, 1.4)	1.2 (1.1, 1.4)	1.3 (1.1, 1.6)
LDL-C (mmol/L)	3.4 (0.9)	3.5 (0.8)	3.4 (1.1)	3.1 (0.9)	3.4 (0.9)
Triglycerides (mmol/L)	1.5 (1.1,2.1)	1.5 (1.1,2.1)	1.5 (0.9,2.2)	1.6 (1.0,2.6)	1.5 (1.2,2.0)
Lipid lowering medication (n (%))	72 (11.0)	27 (12.7)	4 (8.5)	35 (23.0)	6 (2.5)
Diabetes (n (%))	47 (7.2)	6 (2.8)	4 (8.7)	20 (13.2)	17 (7.0)
baPWV (cm/sec)	1346.2 (174.6)	1324.7 (147.9)	1373.4 (174.0)	1431.2 (156.3)	1306.7 (188.6)

BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; PP: pulse pressure; MBP: mean blood pressure; HDL-C: high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; baPWV: Brachial-ankle pulse wave velocity.
* Values are mean (standard deviation, SD), median (interquartile range, IQR) or n (%). 


Table 2. Annual Changes in blood pressure (SBP, DBP, PP and MBP) (n=656) 
	Range	Mean (SD)	Median (IQR)	10th Percentile	90th Percentile	% of >0	P value for the comparison between mean (SD) and zero
Blood pressure (mmHg)
SBP	-7.4, 9.3	0.3 (2.3)	0.3 (-1.1, 1.6)	-2.5	3.0	54.6%	0.001
DBP	-6.1, 6.8	0.6 (1.6)	0.7 (-0.5, 1.5)	-1.4	2.5	64.0%	<0.001
PP	-5.9, 7.6	-0.3 (1.6)	-0.3 (-1.2, 0.5)	-2.2	1.8	39.5%	<0.001
MBP	-6.4, 6.6	0.5 (1.7)	0.6 (-0.6, 1.5)	-1.6	2.5	61.6%	<0.001
SBP: systolic blood pressure; DBP: diastolic blood pressure; PP: pulse pressure; MBP: mean blood pressure; SD: standard deviation; IQR: interquartile range.


Table 3. Association of baseline and annual changes of blood pressure with baPWV progression (systolic, diastolic, pulse and mean arterial pressure) in general linear models (n=656)

	Model1	Model2	Model3	Model4
	Standardized coefficient	P value	Standardized coefficient	P value	Standardized coefficient	P value	Standardized coefficient	P value
SBP								
         Baseline	0.03	.419	0.04	.381	0.03	.513	0.03	.495
Annual Change	0.35	<. 001	0.35	<. 001	0.35	<. 001	0.33	<. 001
DBP      								
         Baseline	0.08	.420	0.08	.077	0.07	.138	0.06	.173
Annual Change	0.38	<. 001	0.37	<. 001	0.37	<. 001	0.35	<. 001
PP								
         Baseline	0.02	.575	0.02	.625	0.02	.639	0.02	.628
Annual Change	0.15	.001	0.14	.001	0.15	.001	0.15	.001
MBP								
         Baseline	0.06	.150	0.06	.144	0.05	.246	0.05	.262
Annual Change	0.39	<. 001	0.39	<. 001	0.39	<. 001	0.37	<. 001

baPWV: brachial-ankle pulse wave velocity; SBP: systolic blood pressure; DBP: diastolic blood pressure; PP: pulse pressure; MBP: mean blood pressure.
Model 1: Adjusted for age, race, and heart rate.
Model 2: Further adjusted for body mass index (BMI), smoking, hypertension medication, and diabetes.
Model 3: Further adjusted for high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides, and lipid lowering medication. 




Table 4. Association of baseline and annual changes in blood pressure (systolic, diastolic, pulse and mean arterial pressure) with baPWV progression (relative annual change >1% versus ≤1% per year) in logistic regression analysis (n=656)

	Model1	Model2	Model3	Model4
	Odds Ratio(95% CI)	P Value	Odds Ratio(95% CI)	P Value	Odds Ratio(95% CI)	P Value	Odds Ratio(95% CI)	P Value
SBP								
Baseline	1.01 (0.99, 1.02)	.367	1.01 (0.99,1.02)	.490	1.00 (0.99,1.02)	.581	1.00 (0.99, 1.02)	.581
Annual Change	1.36 (1.25, 1.49)	<. 001	1.35 (1.24, 1.48)	<. 001	1.35 (1.24, 1.48)	<. 001	1.34 (1.22, 1.47)	<. 001
DBP								
Baseline	1.02 (1.00, 1.04)	.061	1.02 (1.00, 1.04)	.089	1.02 (1.00, 1.04)	.125	1.02 (0.99, 1.04)	.151
Annual Change	1.68 (1.46, 1.92)	<. 001	1.68 (1.46, 1.93)	<. 001	1.69 (1.47, 1.94)	<. 001	1.65 (1.43, 1.90)	<. 001
PP								
Baseline	1.01 (0.99, 1.02)	.613	1.00 (0.98, 1.03)	.819	1.00 (0.98, 1.03)	.832	1.00 (0.98, 1.03)	.867
Annual Change	1.17 (1.04, 1.31)	.009	1.15 (1.02, 1.29)	.002	1.15 (1.02, 1.29)	.025	1.15 (1.02, 1.30)	.025
MBP 								
Baseline	1.01 (1.00, 1.03)	.131	1.01 (0.99, 1.03)	.182	1.01 (0.99, 1.03)	.264	1.01 (0.99, 1.03)	.277
Annual Change	1.65 (1.45, 1.87)	<. 001	1.64 (1.44, 1.86)	<. 001	1.65 (1.45, 1.87)	<. 001	1.61 (1.42, 1.85)	<. 001

baPWV: brachial-ankle pulse wave velocity; SBP: systolic blood pressure; DBP: diastolic blood pressure; PP: pulse pressure; MBP: mean blood pressure; CI: confidence interval. 
Model 1: Adjusted for age, race, and heart rate.
Model 2: Further adjusted for body mass index (BMI), smoking, hypertension medication, and diabetes.
Model 3: Further adjusted for high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides, and lipid lowering medication. 
Model 4: Further adjusted for annual changes in BMI, HDL-C, LDL-C, and triglycerides. 
4.0 	Discussion
4.1	Major Findings
In this study, longitudinal increases in blood pressures (systolic, diastolic, pulse and mean arterial pressure) were independently associated with baPWV progression in a group of multi-ethnic middle-aged men studied over 4-7 years. However, none of the baseline measures of blood pressure was associated with baPWV progression over time. The results suggest that progression of stiffening of arterial walls was affected by longitudinal change of blood pressure rather than its initial level among healthy middle-aged men. Such information suggests that rising BP may be causally related to arterial stiffening. 
4.2	accelarated blood pressure with bapWV progression
A significant positive association of increase in blood pressure with arterial stiffness progression was observed in this study. This finding is in agreement with a recent report from the Baltimore Longitudinal Study of Aging (BLSA) showing that systolic blood pressure is positively associated with atrial stiffness among community-dwelling volunteers with a mean age of 59 years15. However, the BLSA study did not address the relation of initial blood pressure with the longitudinal increase in arterial stiffness. In contrast to the present study, another community-dwelling population based study from Italy observed the dissociation between trajectories of blood pressure and cfPWV over time14. The study participants had a wide age range from 20 to 101 years. Arterial stiffness is recognized as a characteristic feature of vascular aging but mainly after the age of forty years2. The wide age range, starting from as early as twenty years, may explain the inconsistency between the Italian study and our findings as well as those of the BLSA study. 
4.3	initial blood pressure with baPWV progression
Very few studies have taken into account the initial blood pressure as well its longitudinal change while investigating arterial stiffness progression. An important observation of the present study was that the association between baseline blood pressure and baPWV progression was not significant for all four blood pressure measures (systolic, diastolic, pulse and mean arterial pressure). This finding is consistent with some previous studies that addressed the issue of initial blood pressure on prediction of later arterial stiffness progression16,18. A recent report from the Framingham Heart Study, evaluating a total of 1759 male and female participants with a mean age of 60 years, suggested that the antecedent systolic pressure levels were not independently associated with cfPWV increases occurring during the next 4-6 years18. In contrast, a subgroup analysis from the Study of Women's Health Across the Nation (SWAN) Heart Study reported a significant association between baseline systolic blood pressure and cfPWV progression among 303 perimenopausal women with a mean age of 50 years25. The follow-up period of the SWAN Heart Study was very short, with an average of 2.3 years (range: 1.1 - 4.3 years). This may explain the significant relationship observed between the baseline systolic pressure and follow-up arterial stiffness.  
4.4	baPWV versus cfPWV
cfPWV remains the most recognized and established index of arterial stiffness10. Independent of age, blood pressure and other conventional risk factors, cfPWV consistently predicts future cardiovascular events5,6,26,27. As a more automatized and less operator dependent measure of PWV, the most prominent advantage of baPWV is the ease of application and increased reproducibility compared to cfPWV10,21. Currently baPWV is increasingly used in regular clinical settings in Asian countries due to its ease of use and high reproducibility4. Similar to cfPWV, mounting evidence has demonstrated the strong ability of baPWV to predict future cardiovascular events in patients with end-stage renal disease28, hypertension29 and in the general population30,31. Also, a recent meta-analysis indicated that an increase in baPWV by 1 m/s was associated with an increase by 12%, 13% and 6% in cardiovascular events, cardiovascular mortality, and all-cause mortality, respectively7. Despite its clinical significance with regard to predicting cardiovascular morbidity and mortality, little information is available on how the progression of baPWV is affected by various potential risk factors, such as blood pressure. This is the first study to prospectively evaluate the predictive value of blood pressure on baPWV progression prospectively.
4.5	Blood pressure and atrial stiffness
Arterial stiffness is recognized as having a close link with blood pressure; however, the relation is complex. A reinforcing feedback cycle of arterial stiffness and blood pressure increase has been reported previously11,15. Stiffening is a complex process involving structural changes in the arterial walls with aging, including collagen overproduction, elastin degeneration and vascular smooth muscle proliferation32,33. Blood pressure plays an important role in determining arterial wall structures, with remodeling occurring to compensate for changes in wall stress11,34. Conversely, wall stiffening may elicit endothelial injury35 and smaller arterial diameters36, which may raise blood pressure11,25. Our results showing a positive association between increase in blood pressure and arterial stiffness progression is thus biologically plausible. Recent evidence from clinical18 and animal37 studies indicates that arterial wall stiffening may antecede blood pressure rise with regard to initiating the reinforcing feedback cycle. Our observation that baseline blood pressure was not related with later baPWV progression might be explained by the indication above that arterial stiffness precedes the development of hypertension rather than the other way around. 
4.6	Strengths and Limitations
This is the first study to report the association of longitudinal blood pressure changes with baPWV progression in population-based samples of multi-ethnic healthy middle-aged men with a relatively long follow-up period, up to seven years. We examined the association of four blood pressure measures (systolic, diastolic, pulse and mean arterial pressure) with baPWV progression. In addition, our results are based on adjustment for a wide range of cardiovascular risk factors. We were able to test for race differences in the above associations and found none.
Certain limitations of the current study need to be considered when interpreting the findings. Our study only enrolled men aged at 40-49 years; therefore the study results may not be generalizable to women or other age groups. In addition, the study only collected data twice (baseline and follow-up)  across the 4-7 years follow-up, which limited the evaluation of trends in the relation between longitudinal changes in blood pressure and baPWV progression in midlife. There was only single visit for data collection at baseline or follow-up. Determination of a person’s BP is optimally done with several readings over several days, or a 24-hour ambulatory recording. A total of 377 (28.2%) participants were excluded from this analysis due to missing data of baPWV that may introduce selection bias. However, there was no significant difference between the included and excluded participants in their baseline measures of baPWV and blood pressure (Online Data Supplement Table S1). 
We used 1% as the cutoff point of relative annual change in baPWV during the logistic analyses for the effect of blood pressure on baPWV progression. No such cutoff points are reported for relative annual change of baPWV previously. We analyzed the data using cutoff points of 2% and 3% for the same logistic analyses respectively and the results did not change materially (data not shown).
5.0 	Conclusion
In the current study, accelerated blood pressure was a strong predictor of baPWV progression among apparently healthy multinational middle-age men.  An effect of longitudinal rate of blood pressure changes on arterial stiffness progression was consistently observed.
	Cardiovascular disease is the leading cause of death both in the United States and worldwide38; hypertension is the leading remediable risk factor for cardiovascular disease39. The estimated hypertension mortality is 94 million per year globally, which is about as many as all-infectious diseases combined 39. Also, it is the only condition that kills more people globally than tobacco use40.  Blood pressure control is the most effective intervention on prevention of cardiovascular death compared to other known risk factors, such as treatment of hyperlipidemia and aspirin prophylaxis41. Currently, only about half of people with hypertension have it under control in the United States38. From 2003 to 2013, the death rate attributable to high blood pressure increased by 8.2 %, and the actual number of deaths rose 34.7% 38. 
	Our findings emphasize the active role of blood pressure is played on the process of vascular stiffening among asymptomatic men even when in their 40s, indicating that a rise in blood pressure may contribute to more progression of stiffening---a strong predictor of cardiovascular morbidity and mortality. The present study has public health significance with regard to stressing the important practical issues of effectively controlling blood pressure to reduce vascular damage and cardiovascular risks. Future studies are needed to further explore the mechanism and potential causal factors of arterial stiffness and the effective interventions that specially targeting on preventing or ameliorating the process of stiffening in arteries. .
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Table 5. Comparison baseline characters for subjects between who included and excluded
	Inclusion n=656 (63.5%)	Exclusionn=377 (36.5%)	P value
Baseline*			
Age, years	45.2 (2.9)	45.5 (2.7)	0.139
Race / ethnicity, n (%)			<. 0001
       White American 	213 (32.5)	97 (25.7)	
       African American	47 (7.2)	60 (15.9)	
       Japanese American 	152 (23.2)	151 (40.1)	
       Japanese in Japan	244 (37.2)	69 (18.3)	
BMI, kg/m2	26.3 (4.3)	28.1 (5.7)	<. 0001 
Smoking ≥20 pack-years, n (%)	141 (21.5)	67 (17.8)	0.080
Heart Rate, bpm	65.1 (8.8)	67.0 (10.1)	0.003
SBP, mmHg	124.6 (13.8)	126.2 (13.9)	0.080
DBP, mmHg	75.4 (10.4)	76.2 (10.4)	0.244
PP, mmHg	49.3 (7.7)	50.1 (8.1)	0.119
MBP, mmHg	91.8 (11.1)	92.9 (11.1)	0.144
Table 5 Continued
Hypertension medication, n (%)	66 (10.1)	60 (15.9)	0.006
HDL-C, mmol/L	1.3 (1.1,1.5)	1.3 (1.1,1.5)	0.495
LDL-C, mmol/L	3.4 (0.9)	3.3 (1.0)	0.507
Triglycerides, mmol/L	1.5 (1.1,2.1)	1.5 (1.0,2.1)	0.522
Lipid lowering medication, n(%)	72 (11.0)	56 (14.9)	0.069
Diabetes, n (%)	47 (7.2)	38 (10.1)	0.062
baPWV, cm/s	1346.2 (174.6)	1371.1 (197.3)	0.058

BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; PP: pulse pressure; MBP: mean blood pressure; HDL-C: high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; baPWV: Brachial-ankle pulse wave velocity.
* Values are mean (standard deviation, SD), median (interquartile range, IQR) or n (%). 













SBP: systolic blood pressure; DBP: diastolic blood pressure; PP: pulse pressure; MBP: mean blood pressure.
* In addition to blood pressure (SBP, DBP, PP, or MBP), race and their interaction term, the model also adjusted for age, follow-up time, heart rate, body mass index (BMI), frequency of smoking (≥20 pack-years), diabetes, hypertension medication, high-density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), triglycerides, lipid lowering medication, as well as annual changes in BMI, HDL-C, LDL-C, and triglycerides. 
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